Market Overview

Corporate Reputation of Pharma Companies, 2017-2018 - Patient Perspective from Bleeding-Disorders Patients -


The "The
Corporate Reputation of Pharma Companies, 2017 - The Patient Perspective
- Bleeding-Disorders Edition"
report has been added to's

State of relationships between bleeding-disorders patient groups and the
pharmaceutical industry

The worldwide incidence of one of the most high profile of the bleeding
disorders - haemophilia - is not well known. However, the US-based
Centers for Disease Control (CDC) estimates that this particular
condition affects more than 400,000 people, with as many as 75% of these
individuals (mostly people living in poorer parts of the world) still
receiving inadequate treatment for their bleeding disorder - or, indeed,
no access to treatment at all. A large number of the comments made to
the 2017 Corporate-Reputation survey by respondent bleeding-conditions
patient groups underscored the problems associated with significant
worldwide geographic inequities of bleeding-disorders treatments.

Patient groups which specialise in such conditions have particularly
high expectations of the pharma companies that deliver treatments for
bleeding disorders. These patient groups asked for pharmaceutical
companies to put more effort into socially-responsible activities, and
to be especially sensitive to the needs of patients with a bleeding

Key Topics Covered:

  1. Executive Summary
  2. The Relationships That Bleeding-Disorders Patient Groups Have With
    Pharma, 2017
  3. Industry-Wide Findings From Bleeding-Disorders Patient Groups, 2017
  4. Rankings Of The 9 Pharma Companies, 2017 V. 2016 Among
    Bleeding-Disorders Patient Groups Familiar With The Companies
  5. Positioning Of 5 Pharma Companies, 2017 V. 2016 Among
    Bleeding-Disorders Patient Groups That Work/Partner With The Companies
  6. Profiles Of The 9 Companies, 2017

Companies Mentioned

  • Bayer
  • Biogen
  • CSL Behring
  • Grifols
  • Novo Nordisk
  • Octapharma
  • Pfizer
  • Roche/Genentech
  • Shire

For more information about this report visit

View Comments and Join the Discussion!